Ibrutinib is a novel inhibitor of Btk that has significant antitumor activity towards relapsed and refractory CLL, mantle-cell lymphoma and is currently in clinical trials for DLBCL [36, 37]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.